Private company

Cerevel Therapeutics Holdings, Inc.

American pharmaceutical preparations company, incorporated in Delaware1

In its 2024 annual report the company says: “We are a clinical-stage biopharmaceutical company pursuing a targeted approach to neuroscience that combines a deep understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system, or CNS, target receptor selective pharmacology to discover and design new therapies.”3 It is headquartered in Cambridge, Massachusetts.1

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersCambridge, Massachusetts1
  • Incorporated inDE2
  • Business address222 Jacobs Street, Suite 200, Cambridge, Ma 021412
  • Filer categoryLarge accelerated filer2

See how the biggest companies compare on our leaderboards

We are a clinical-stage biopharmaceutical company pursuing a targeted approach to neuroscience that combines a deep understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system, or CNS, target receptor selective pharmacology to discover and design new therapies. We seek to transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder and Parkinson’s disease. We are advancing our extensive and diverse pipeline with numerous clinical trials underway or planned, including three ongoing Phase 3 trials and an open-label extension trial for tavapadon in Parkinson’s, two ongoing Phase 2 trials and an open-label extension trial for emraclidine in schizophrenia, an ongoing Phase 2 proof-of-concept trial and an open-la…3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-64.2%Return on equity4
0.56×Debt to equity4
-$346.1MFree cash flow4

Financial statements

Revenue5674$0 in 2023
02020: $0$020202021: $0$020212022: $0$020222023: $0$02023
Operating income674-$447.3M in 2023+436% since 2019
-$600.0M-$400.0M-$200.0M02019: -$83.5M-$83.5M20192020: -$149.1M-$149.1M2020+79%2021: -$220.1M-$220.1M2021+48%2022: -$367.8M-$367.8M2022+67%2023: -$447.3M-$447.3M2023+22%
Net income674-$432.8M in 2023+237% since 2019
-$600.0M-$400.0M-$200.0M02019: -$128.4M-$128.4M20192020: -$152.1M-$152.1M2020+19%2021: -$225.3M-$225.3M2021+48%2022: -$351.5M-$351.5M2022+56%2023: -$432.8M-$432.8M2023+23%
Fiscal year201820192020202120222023
Revenue$05$06$07$04
Research and development$50.3M6$103.3M7$161.9M4$280.3M4$334.6M4
Operating expenses$220.1M4$367.8M4$447.3M4
Operating income-$83.5M6-$149.1M7-$220.1M4-$367.8M4-$447.3M4
Interest$3.9M4$10.6M4
Income before tax-$225.3M4-$351.4M4-$432.3M4
Income tax$45.0K6-$24.0K7$160.0K4$503.0K4
Net income-$128.4M6-$152.1M7-$225.3M4-$351.5M4-$432.8M4
Earnings per share-$2.017-$1.654-$2.324-$2.674
Earnings per share (diluted)-$2.017-$1.654-$2.324-$2.674
Shares (weighted, basic)136.6M shares4151.3M shares4162.1M shares4
Shares (weighted, diluted)136.6M shares4151.3M shares4162.1M shares4

Compare Cerevel Therapeutics Holdings, Inc. with another company

Corporate structure

Cerevel Therapeutics Holdings, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Cerevel Therapeutics Holdings, Inc.

  • BC Perception Holdings, LP Filed SC 13D/A on Cerevel Therapeutics Holdings, Inc., latest Aug 5, 2024 (5 filings since Mar 3, 2022)
  • Pfizer Filed SC 13D/A on Cerevel Therapeutics Holdings, Inc., latest Aug 5, 2024 (3 filings since Apr 7, 2022)
  • FMR LLC Filed SC 13G/A on Cerevel Therapeutics Holdings, Inc., latest May 10, 2024 (4 filings since Feb 9, 2022)
  • PERCEPTIVE ADVISORS LLC Filed SC 13D/A on Cerevel Therapeutics Holdings, Inc., latest Oct 17, 2023 (3 filings since Apr 21, 2023)
  • Cerevel Therapeutics Holdings, Inc. Cambridge, Massachusetts

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Cerevel Therapeutics Holdings, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Accumulated depreciation$12.6M4 Dec 31, 2023$7.3M4 Dec 31, 2022+73.1%
Property and equipment, net$25.6M4 Dec 31, 2023$27.5M4 Dec 31, 2022−6.6%
Operating-lease assets (leased space)$20.1M4 Dec 31, 2023$21.8M4 Dec 31, 2022−7.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$416.5M4 Dec 31, 2023$136.5M4 Dec 31, 2022+205.1%
Marketable securities, current$574.5M4 Dec 31, 2023$755.5M4 Dec 31, 2022−24.0%
Marketable securities, non-current$185.2M4 Dec 31, 2023$58.1M4 Dec 31, 2022+218.6%
Debt securities available for sale$759.7M4 Dec 31, 2023$813.6M4 Dec 31, 2022−6.6%

Leadership

Who has led Cerevel Therapeutics Holdings, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Adam Leo Stone2020
  2. Ronald C. Renaud Jr.2023–2024

President

  1. Abraham Ceesay2021–2023
  2. Ronald C. Renaud Jr.2023–2024

Chief financial officer

  1. Michael Seth Altman2020
  2. Kathy Yi2020–2021
  3. Susan Altschuller2023–2024
2025
Board members and other officers (26)

Former names

  • ARYA Sciences Acquisition Corp IIMar 10, 2020 to Oct 26, 20202

Timeline

  1. Aug 1, 20248-K Entered a material agreement; Completed an acquisition or sale; Listing notice or transfer40
  2. Feb 16, 20248-K Shareholder vote; Other events41
  3. Dec 7, 20238-K Entered a material agreement; Regulation FD disclosure; Other events42
  4. Nov 1, 20238-K Results of operations43
  5. Oct 12, 20238-K Entered a material agreement; Other events44
  6. Oct 11, 20238-K Results of operations; Regulation FD disclosure45
  7. Aug 2, 20238-K Results of operations46
  8. Jun 14, 2023New chief executive Ronald C. Renaud Jr. becomes CEO11
  9. Jun 8, 20238-K Shareholder vote47
  10. May 10, 20238-K Executive or director change; Regulation FD disclosure48
  11. May 3, 20238-K Results of operations; Executive or director change49
  12. Feb 22, 20238-K Results of operations; Executive or director change50
  13. Jan 9, 20238-K Other events51
  14. Jun 4, 2020New chief executive Adam Leo Stone becomes CEO12

Calendar

When it reported results

  1. Nov 1, 2023Reported quarterly or annual results43
  2. Oct 11, 2023Reported quarterly or annual results45
  3. Aug 2, 2023Reported quarterly or annual results46
  4. May 3, 2023Reported quarterly or annual results49
  5. Feb 22, 2023Reported quarterly or annual results50
  6. Nov 8, 2022Reported quarterly or annual results52
  7. Aug 1, 2022Reported quarterly or annual results53
  8. May 10, 2022Reported quarterly or annual results54

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

272 filings to the SEC since October 2021: 5 annual reports, 8 quarterly reports, 21 major events, 151 insider forms, 15 large holders, 72 other. The latest 20:

  1. Aug 12, 202415-12G EDGAR
  2. Aug 5, 2024EFFECT EDGAR
  3. Aug 5, 2024EFFECT EDGAR
  4. Aug 5, 2024EFFECT EDGAR
  5. Aug 5, 2024EFFECT EDGAR
  6. Aug 5, 2024SC 13D/A EDGAR
  7. Aug 5, 20244 EDGAR
  8. Aug 5, 20244 EDGAR
  9. Aug 5, 20244 EDGAR
  10. Aug 5, 20244 EDGAR
  11. Aug 5, 20244 EDGAR
  12. Aug 5, 20244 EDGAR
  13. Aug 5, 20244 EDGAR
  14. Aug 5, 20244 EDGAR
  15. Aug 5, 20244 EDGAR
  16. Aug 5, 20244 EDGAR
  17. Aug 5, 20244 EDGAR
  18. Aug 5, 20244 EDGAR
  19. Aug 5, 20244 EDGAR
  20. Aug 5, 20244 EDGAR

The 272 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

75 open-market trades by officers, directors and large owners since October 2021: 7 buys and 68 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 1, 2024COLES N ANTHONYDirectorSale25,000$41.18$1.0MForm 4
Jun 3, 2024COLES N ANTHONYDirectorSale50,000$40.61$2.0MForm 4
May 10, 2024COLES N ANTHONYDirectorSale50,000$42.10$2.1MForm 4
Apr 1, 2024COLES N ANTHONYDirectorSale50,000$42.33$2.1MForm 4
Mar 4, 2024COLES N ANTHONYDirectorSale50,000$41.01$2.1MForm 4
Feb 29, 2024COLES N ANTHONYDirectorSale50,000$41.16$2.1MForm 4
Feb 7, 2024Renger JohnChief Scientific OfficerSale2,161$41.54$89.8KForm 4
Feb 7, 2024COLES N ANTHONYDirectorSale2,506$41.54$104.1KForm 4
Jan 2, 2024COLES N ANTHONYDirectorSale50,000$42.24$2.1MForm 4
Dec 26, 2023Sanchez RamiroChief Medical OfficerSale10,000$42.47$424.7KForm 4
Dec 22, 2023DiPietro KennethChief Human Resources OfficerSale8,000$41.45$331.6KForm 4
Dec 20, 2023Bodenrader MarkSee RemarksSale7,889$41.42$326.8KForm 4
Dec 20, 2023DiPietro KennethChief Human Resources OfficerSale6,256$41.42$259.1KForm 4
Dec 20, 2023Akamine ScottChief Legal OfficerSale7,072$41.42$292.9KForm 4
Dec 20, 2023Sanchez RamiroChief Medical OfficerSale10,152$41.42$420.5KForm 4
Dec 20, 2023ALTSCHULLER SusanChief Financial OfficerSale13,808$41.42$571.9KForm 4
Dec 20, 2023Tregoning KathleenSee RemarksSale6,288$41.42$260.4KForm 4
Dec 15, 2023Sanchez RamiroChief Medical OfficerSale7,500$41.39$310.4KForm 4
Dec 7, 2023Sanchez RamiroChief Medical OfficerSale10,000$41.37$413.7KForm 4
Dec 7, 2023Akamine ScottChief Legal OfficerSale10,000$41.37$413.7KForm 4

All 75 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Cerevel Therapeutics Holdings, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCerevel Therapeutics Holdings, Inc.1
  • CIK0001805387
  • Filer statusLarge accelerated filer1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address222 Jacobs Street, Suite 200, Cambridge, MA 021411
  • Phone844-304-20481
  • Shares outstanding182,194,722 as of Apr 26, 202410
  • Public float$2.2B as of Jun 30, 202359
  • On EDGAR sinceMar 10, 20201
  • Filings448 in all: 4 (188), 8-K (45), 3 (37), 144 (27), 424B3 (15), EFFECT (13), SC 13D/A (13), 10-Q (12)1
    All 42 form types

    CORRESP (11), SC 13G/A (7), 425 (6), POS AM (6), UPLOAD (6), 424B5 (5), DEFA14A (5), 10-K (4), 25-NSE (3), 5 (3), DEF 14A (3), S-1 (3), S-3 (3), S-8 (3), S-8 POS (3), SC 13D (3), SC 13G (3), 10-K/A (2), 424B4 (2), DRS (2), S-4/A (2), 144/A (1), 15-12G (1), 8-A12B (1), 8-K/A (1), ARS (1), CERT (1), DEFM14A (1), DRS/A (1), PREM14A (1), PRER14A (1), S-1/A (1), S-1MEF (1), S-4 (1)

  • Latest filingsAnnual report (10-K) Feb 27, 2024
    Quarterly report (10-Q) May 8, 2024
    Proxy statement (DEF 14A) Apr 28, 2023
    Latest 8-K (8-K) Aug 1, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
    SEC EDGAROther events
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59